In this roundtable discussion published in Corporate Disputes, Sean Sheridan and two other panelists discuss recent trends in patent disputes. Dr. Sheridan dicusses the sharp decline in petitions for inter partes review filed at the Patent Trial and Appeal Board (PTAB) as well an an increase in the number of bills seeking to limit patent protection for pharmaceutical and biologic products.
Click the link below to download a PDF of the article.
China refines how to determine patent damages
China’s patent law was promulgated in 1984 and amended three times prior to 2020 (in 1992, 2000, and 2008). On October 17, 2020, the National People’s Congress...